The markets are up slightly ahead of the open. Some U.S. economic data came out at 8:30 AM ET, most notably, the weekly jobless claims number. New jobless claims came in at 244K, slightly higher than the consensus estimate of 242K. However, the number of people who are continuously receiving jobless benefits fell by 49K for the week ended on April 8, which was the lowest level since April 2000. Moreover, the Philadelphia Fed Business Outlook Survey data was released, and the General Business Conditions Index level came in at 22.0, economists were expecting 25.5. Enough with economics. There were some small-cap stocks moving ahead of the open, and here’s what some stocks traders are watching today.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) was granted orphan designation by the U.S. Food and Drug Administration (FDA) for its treatment of congenital ichthyosis. The date that the drug was designated was on April 17, 2017, according to the FDA. After the company was granted orphan designation, shares rose by over 5% during the pre-market.
Here’s a look at ALDX on the daily chart:
Whitestone REIT (NYSE: WSR) are down just over 7% during the premarket, after the company filed to sell 8.1M shares of its common stock. Additionally, in the company’s Form 424B5, it stated that the underwriters could exercise their option to purchase up to an additional 1.215M shares from the company, at the public offering price, within 30 days after the date of the prospectus supplement. WSR had 29.8M shares outstanding and 28.59M floating, based on its most recently filed quarterly report.
Here’s a look at the stock during the premarket:
Source: Google Finance
Here’s a look at MZOR on the daily chart:
Hexcel Corporation(NYSE:HXL) reported its first quarter 2017 results yesterday. The company had a GAAP diluted EPS of 70 cents, and an adjusted diluted EPS of 60 cents. Hexcel’s net sales for 1Q 2017 fell by 3.8% year over year. Moreover, its adjusted net income for 1Q 2017 fell by 0.9% from its reported adjusted net income in 1Q 2016. Hexcel also issued guidance, and it maintained its FY 2017 adjusted diluted EPS guidance, which is projected to come in between a range of $2.64 and $2.76. However, the company lowered its FY 2017 sales guidance to a range between $2B and $2.08B.
Here’s a look at the stock during the after hours, yesterday:
Source: Google Finance